Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once a month in the acute and maintenance treatments of schizophrenia. It has been reported to be successful especially in patients with poor oral drug compliance. The most common side effects are dizziness, sleepiness, anxiety, injection site reactions, and extrapyramidal system symptoms. The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose.

___

1. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007; 115:260-267.

2. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006; 67(Suppl 5):15-18.

3. Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 2012; 12:26.

4. Cleton A, Rossenu S, Hough D, Crauwels H, Vandebosch A, Berwaerts J, et al. Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Poster presented at the American Society for Pharmacology and Therapeutics (PI-75). Orlando, FL, 2008 Apr 2-5. Clin Pharmacol Ther 2008; 83:S31

5. Cleton A, Rossenu S, Hough D, Crauwels H, Berwaerts J, Gopal S, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg EG. A new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles. Poster presented at American Society for Clinical Pharmacology and Therapeutics (PI-74). Orlando, FL, 2008 Apr 2–5. Clin Pharmacol Ther 2008; 83:S31

6. Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2010; 7:561-572.

7. Kane JM, Barett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004; 65:1447-1455.

8. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (Suppl 1):S7-S14.

9. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl 18):36-46.

10. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010; 25:247-256.

11. Fujii Y. What lessons should we learn from the death of patients on Xeplion? Psychiatry Clin Neurosci 2015; 117:132-45. (Japanese with English abstract)

12. Omi T, Kanai K, Kiguchi T, Nishida T, Fujimi S, Matsunaga H. The possibility of the treatment for long-acting injectable antipsychotics induced severe side effects. Am J Emerg Med 2017; 35:1211e1-1211e2.

13. Mirza H, Harding D, Al-Balushi N. Paliperidone palmitate-induced delirium in an adolescent with schizophrenia: case report. Sultan Qaboos Univ Med J 2018; 18:e208-e210.

14. Onen S. Liver enzyme elevation after first dose of paliperidone palmitate: a case report. Bulletin of Clinical Psychopharmacology 2014; 24 (Suppl 1):S287.

15. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-1087.

16. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196:434-439.

17. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010; 13:635-647.

18. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010; 35:2072-2082.

19. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010; 30:235-244.

20. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 2001;21:215-22.

21. Ouanes S, Damak R, Hajri M, Cherif W, Chennoufi L, Cheour M. Haloperidol-induced cytolytic hepatitis. Eur Psychiatry 2015;30 (Suppl 1):1597.

22. Gabriel R, Wojtanowicz T, Farokhpay R, Bota R. Acute transaminitis after initial days of starting haloperidol. Ment Illn 2019;11:33-35.

23. Saglam O, Bahsi R, Akkoca Y, Filik L. Risperidone-induced hepatotoxicity in a patient addicted to synthetic cannabinoid. Eur J Gastroenterol Hepatol 2016; 8:360-361.

24. Yagcioglu EA, Gurel SC. Atypical antipsychotics: In Yuksel N (editor). Basic Psychopharmacology. Ankara: Psychiatric Association of Turkey Inc., 2010, 832-833. (Turkish)

25. Paulzen M, Orfanos S, Grunder G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry 2010; 167:351-352.
Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi-Cover
  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984
  • Yayıncı: Kare Yayıncılık
Sayıdaki Diğer Makaleler

The gut microbiome integrates immune-inflammatory processes in depression

George ANDERSON

A serious dermatological side effect due to vortioxetine: a case report

Burak OKUMUS, Kader Semra KARATAS, Asli Enzel KOC

Typical Rett Syndrome in a young boy with hemizygous c.316C>T mutation in MECP2 gene

Murat COSKUN, Ilyas KAYA, Zeynep Nur GULLE, Seda ERBİLGİN, Ibrahim AKALİN, Afig BERDELİ

Associations between sleep quality, severity of dissociation, pathological worry, and functional impairment in multiple sclerosis: a case-control study

Abdullah YİLDİRİM, Murat BOYSAN, Vedat CİLİNGİR

What is the role of emotional regulation and psychological rigidity in the relationship between stress and pathological Internet use?

Elcin YORULMAZ, Orcun YORULMAZ, Umut CİVGİN

Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report

Esin ERDOGAN, Dursun Hakan DELİBAS

Psychometric validation of the Turkish Ten-Item Internet Gaming Disorder Test (IGDT-10)

Cuneyt EVREN, Bilge EVREN, Nilay KUTLU, Ercan DALBUDAK, Merve TOPCU

Cognitive functions in opioid-dependent males according to duration of abstinence

Buket KOPARAL, Ceyda Oktay YANİK, Ismail Volkan SAHİNER, Hatice Ayca KALOGLU, Muhammed Hakan AKSU, Cisem UTKU, Zehra ARİKAN

Mediating effects of self-esteem in the relationship between attachment styles and social media addiction among university students

Zeynep Isil DEMİRCİOGLU, Asli Goncu KOSE

The validity and reliability of the Turkish brief version of the Zimbardo Time Perspective Inventory for adolescents

Ercan KOCAYORUK, Omer Faruk SİMSEK